Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 139 of 144 pages ‹ First < 137 138 139 140 141 > Last ›
HSL19532
Pear R
Spending on Prescription Drugs Increases by Almost 19 Percent
The New York Times 2001 May 8
http://www.nytimes.com/2001/05/08/us/spending-on-prescription-drugs-increases-by-almost-19-percent.html
HSL20363
Charatan F
Doctors say they are not influenced by drug companies' promotions
BMJ 2001 May 5; 322:(7294):1081
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1120227/
HSL2324
Peterson , R G.
Cisapride and patient information leaflets
CMAJ 2001 May 1; 164:(10):1278
HSL2325
Muller , P .
Cisapride and patient information leaflets
CMAJ 2001 May 1; 164:(9):1278
HSL2326
Arnott , W .
Cisapride and patient information leaflets
CMAJ 2001 May 1; 164:(9):1278
HSL2507
Zitner D.
Prescription data (3rd of 5 letters)
Canadian Medical Association Journal 2001 May 01; 164:(10):1408-9
HSL2512
Sukkari S, Sasich , L .
Cisapride and patient information leaflets (1st of 4 letters)
Canadian Medical Association Journal 2001 May 1; 164:(9):1276-1278
HSL2541
Peterson R.
Cisapride and patient information leaflets (4th of 4 letters)
Canadian Medical Association Journal 2001 May 1; 164:(9):1278-9
HSL2546
Muller P.
Cisapride and patient information leaflets (3rd of 4 letters)
Canadian Medical Association Journal 2001 May 1; 164:(9):1278
HSL2573
Arnott W.
Cisapride and patient information leaflets (2nd of 4 letters)
Canadian Medical Association Journal 2001 May 1; 164:(9):1278
HSL35
Stout E.
Doctoring sales
Sales & Marketing Management 2001 May; 52-60
HSL1851
Steinman MA, Shlipak MG, McPhee SJ.
Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions.
Am J Med 2001 May; 110:(7):551-7
http://linkinghub.elsevier.com/retrieve/pii/S000293430100660X
HSL2095
Kluger AN, Tikochinsky J.
The error of accepting the "theoretical" null hypothesis: the rise, fall, and resurrection of commonsense hypotheses in psychology.
Psychol Bull 2001 May; 127:(3):408-23
http://content.apa.org/journals/bul/127/3/408
HSL7410
Gutknecht DR.
Evidence-based advertising?: A survey of four major journals.
J Am Board Fam Pract. 2001 May-Jun;14(3):197-200. 2001 May-Jun; 14:(3):197-200
http://www.jabfm.org/cgi/reprint/14/3/197
HSL7802
Mudryj L, Richardson H.
Cyber prescriber
New Zealand Pharmacy 2001 May; 21:(33):
HSL7819
Gannon K.
Manufacturers share their thoughts about pharmacists
Hospital Pharmacist Report 2001 May; 15:35-36
HSL18005
Berger JT, Kark P, Rosner F, Packer S, Bennett AJ.
Direct-to-consumer drug marketing: public service or disservice?
Mt Sinai J Med 2001 May; 68:(3):197-202
http://www.ncbi.nlm.nih.gov/pubmed/11373692
HSL18006
Hassan F.
Being a modern pharmaceutical company: new paradigms for the pharmaceutical industry.
Clin Pharmacol Ther 2001 May; 69:(5):281-5
http://www.ncbi.nlm.nih.gov/pubmed/11371995
HSL20523
Harris G
AIDS Gaffes in Africa Come Back To Haunt Drug Industry in the U.S.
The Wall Street Journal 2001 Apr 23
http://online.wsj.com/article/SB987984200345114882.html
HSL2561
Hogh B, Clarke PD, Camus D, Chulay JD.
Efficacy of atovaquone-proguanil? (2nd of 2 letters)
The Lancet 2001 Apr 21; 357:1289-1290
HSL2567
Croft A, Geary K, Morgan L.
Efficacy of atovaquone-proguanil? (1st of 2 letters)
The Lancet 2001 Apr 21; 357:1289
HSL2021
McIlroy A.
Article censored that decried placebo use in drug trials
The Globe and Mail 2001 Apr 18
HSL7840
Relman AS.
Separating continuing medical education from pharmaceutical marketing.
JAMA 2001 Apr 18; 285:(15):2009-12
http://jama.ama-assn.org/cgi/content/full/285/15/2009
HSL7842
Holmer AF.
Industry strongly supports continuing medical education.
JAMA 2001 Apr 18; 285:(15):2012-4
HSL7838
Cassell D.
How manufacturers view pharmacists
Drug Topics 2001 Apr 16; 145:47-48, 50, 52, 54
HSL2372
Kiln , M .
Industry-sponsored research
The Lancet 2001 Apr 14; 357:1209-1210
HSL2565
The tightening grip of big pharma
Lancet 2001 Apr 14; 357:(9263):1141
http://linkinghub.elsevier.com/retrieve/pii/S0140673600043634
HSL2676
Anonymous .
Rebirth of a salesman
The Economist 2001 Apr 14
HSL20126
Jennings L
Justification easy for influenza campaign
New Zealand Doctor 2001 Apr 118
HSL2371
Kondro W.
Canadian university publishes new rules to protect scientists.
Lancet 2001 Apr 7; 357:(9262):1104
http://linkinghub.elsevier.com/retrieve/pii/S0140673600043221
HSL7843
Gebhart F.
Annual Rx survey: behind the numbers
Drug Topics 2001 Apr 2; 145:48-50, 52, 55
HSL1852
Sluzki CE.
Drug-company influence on medical education in the U.S
Am J Orthopsychiatry. 2001 Apr; 71:(2):148-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11347356&query_hl=7
HSL1853
Johnson RG.
Physician education and the pharmaceutical industry.
Chest 2001 Apr; 119:(4):995-6
http://www.chestjournal.org/cgi/content/full/119/4/995
HSL2369
Franklin , A .
Pharmaceutical companies and CME
OMR 2001 Apr; 68:(4):10
HSL2370
Goodman B.
Do drug company promotions influence physician behavior?
West J Med 2001 Apr; 174:(4):232-3
HSL7812
TI: Joint statement from CP and PGEU: Prescription-only medicines should not be advertised directly to the public
Farmaceutski Glasnik 2001 Apr; 57:153-154
HSL18007
Varkey B.
Time for introspection.
Chest 2001 Apr; 119:(4):1255-6
http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=11296195
HSL18008
Lever A.
Considerations in the Relationship Between the American College of Chest Physicians and Industry
Chest 2001 Apr; 119:(4):1257-9.
http://chestjournal.chestpubs.org/content/119/4/1257.long
HSL2365
Lo B, Wolf L .
Conflict-of-interest policies
NEJM 2001 Mar 29; 344:(13):1018
HSL2366
McCrary , S. V, L B.Brody, B A.
Conflict-of-interest policies
NEJM 2001 Mar 29; 344:(13):1018
HSL2367
Nurok , M .
Conflict-of-interest policies
NEJM 2001 Mar 29; 344:(13):1017
HSL2368
Topol , E J.
Conflict-of-interest policies
NEJM 2001 Mar 29; 344:(13):1017
HSL2511
Topol E.
Conflict-of-interest policies (1st of 6 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1017
HSL2540
Ratain M.
Conflict-of-interest policies (3rd of 6 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1018
HSL2543
Nurok M.
Conflict-of-interest policies (2nd of 6 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1017
HSL2548
Miller F.
To protect those who serve (1st of 2 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1018-9
HSL2555
McCrary SV, McCullough LB, Brody BA.
Conflict-of-interest policies (5th of 6 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1018
HSL2556
Martin J, Kasper D.
Conflict-of-interest policies (6th of 6 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1018
HSL2558
Lo B, Wolf L.
Conflict-of-interest policies (4th of 6 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1018
HSL2566
Drazen J, Koski G.
To protect those who serve (2nd of 2 letters)
New England Journal of Medicine 2001 Mar 29; 344:(13):1019
HSL2030
Dieperink ME, Drogemuller L.
Industry-sponsored grand rounds and prescribing behavior.
JAMA 2001 Mar 21;
http://jama.ama-assn.org/cgi/content/full/285/11/1443
HSL2020
Byrne M.
Drug makers to operate in a new market
Australian Financial Review 2001 Mar 14
HSL10212
Willman D.
Risk Was Known as FDA OK'd Fatal Drug
Los Angeles Times 2001 Mar 11
http://www.lef.org/magazine/mag2001/june2001_report_fda.html
HSL19533
Hall SS
Claritin and Schering-Plough: A Prescription for Profit
The New York Times 2001 Mar 11
http://www.nytimes.com/2001/03/11/magazine/11CLARITIN.html?pagewanted=all
HSL17979
Henry DA, Birkett DJ.
Changes to the Pharmaceutical Benefits Advisory Committee.
Med J Aust 2001 Mar 5; 174:(5):209-10
http://www.mja.com.au/public/issues/174_05_050301/henry/henry.html
HSL20168
Silversides A
Under the counter: Pharmaceutical companies are pushing the boudnaries of the law against direct-to-consumer drug advertising
Eye Weekly 2001 Mar 5
http://contests.eyeweekly.com/eye/issue/issue_05.03.01/news/drugs.php
HSL5299
Marshall JN, Stewart M, Ostbye T.
Small-group CME using e-mail discussions. Can it work?
Can Fam Physician 2001 Mar 01; 47:557-63
HSL2364
Belkin , L .
Prime time pushers
2001 Mar; 31-37
http://motherjones.com/magazine/MA01/drug.html
HSL2542
Perkin R.
Why the PAAB is important
Annals RCPSC 2001 Mar; 34:(2):105
HSL7820
White K, Beall T.
Changing OTC landscape
Pharmaceutical Executive 2001 Mar; 21:82, 84, 86, 88, 90
HSL7821
Bernacchi T.
Challenge of prescription drug pricing
Pharmaceutical Executive 2001 Mar; 21:56-58, 60, 62, 64, 66, 68
HSL15544
Morris LA, Pines WL.
Regulating Future Pharmaceutical Promotion.
Medical Marketing & Media 2001 Mar; 36:(3):62
http://www.mmm-online.com/issuearchive/
HSL2019
Noonan D.
GM's War on Drug Costs.
Newsweek 2001 Feb 2646
HSL2363
GM's war on drugs
Newsweek 2001 Feb 26; 46-48
HSL2349
Buffett L , McCormick W
Unwanted freebies
CMAJ 2001 Feb 20; 164:(4):464
HSL2353
Gold , A .
A drug by any other name
CMAJ 2001 Feb 20; 164:(4):464
HSL2354
Hoey , J .
A drug by any other name
CMAJ 2001 Feb 20; 164:(4):464
HSL2562
Hoey J.
A drug by any other name (response)
Canadian Medical Association Journal 2001 Feb 20; 164:(4):464
HSL2018
Jackson L.
Paying the Price
Australian Brodcasting Corporation: 4 Corners 2001 Feb 19
http://www.abc.net.au/4corners/stories/4Cprograms_PAYINGTHE.htm
HSL19534
Shapiro JP, Schultz S.
Prescriptions: how your doctor makes the choice.
US News World Rep 2001 Feb 19; 130:(7):58-61
http://www.ncbi.nlm.nih.gov/pubmed/11225095
HSL19778
Hittmann G
Undue Influence?
Australian Doctor 2001 Feb 16
HSL19824
Reuters
Dietary Supplement Recalled for Containing Prescription Anxiety Drug
MedScape 2001 Feb 16
HSL2352
Weber W.
Sponsored continuing medical education under scrutiny in Europe
Lancet 2001 Feb 10; 357:452
HSL8833
Gupta S.
Why le Carre’s ThreeBees will not sting India : Trust our immune system
Indian Express (Mumbai) 2001 Feb 10
http://www.expressindia.com/ie/daily/20010227/shekhar.htm
HSL20138
Mesley W
The battle over a drug ad
Undercurrents : CBC-TV 2001 Feb 40
HSL2362
Sibbald , B .
Doctors asked to take pledge to shun drug company freebies
CMAJ 2001 Feb 01; 164:(4):531
HSL2351
Lal A.
Pharmaceutical drug promotion: how it is being practiced in India?
J Assoc Physicians India 2001 Feb; 49:266-73:
HSL18009
McGettigan P, Golden J, Fryer J, Chan R, Feely J.
Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message.
Br J Clin Pharmacol 2001 Feb; 51:(2):184-9
http://www3.interscience.wiley.com/journal/118991090/abstract
HSL2350
Therapeutic Products Programme.
Advertising Standards Canada and the Therapeutic Product Programme's roles and consultation related to advertising review and complaint adjudication
2001 Jan 22;
http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/policy/issued/advcaf_e.pdf
HSL7835
Van Diepen LR.
Pharmaceutical manufacturer assistance programs for indigent patients: solution or symptom?
Am J Health Syst Pharm 2001 Jan 15; 58:(2):162-3
http://www.ajhp.org/cgi/reprint/58/2/162
HSL7898
Mehl B, Santell J.
Projecting future drug expenditures--2001.
Am J Health Syst Pharm 2001 Jan 15; 58:(2):125-33
http://www.ajhp.org/cgi/reprint/58/2/125
HSL7899
Weiner S, Dischler J, Horvitz C.
Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program.
Am J Health Syst Pharm 2001 Jan 15; 58:(2):146-50
http://www.ajhp.org/cgi/reprint/58/2/146
HSL7901
Kennedy A.
Additional Novartis products available through assistance programs
American Journal of Health System Pharmacy 2001 Jan 1; 58:79
HSL4940
Jesani A.
Calls for advertising and market reforms in health care.
Issues Med Ethics 2001 Jan-Mar; 9:(1):19
HSL4941
Mamdani B, Mamdani M.
Ethics of professional advertising.
Issues Med Ethics 2001 Jan-Mar; 9:(1):18
HSL4942
Malpani A.
Doctors should be allowed to advertise.
Issues Med Ethics 2001 Jan-Mar; 9:(1):16-7
HSL4943
Pandya SK.
Advertising remains unethical even in the digital age.
Issues Med Ethics 2001 Jan-Mar; 9:(1):15
HSL7825
Cloutier M, Golenski J.
RxHealthValue offers three recommendations and cost research
Journal of Managed Care Pharmacy 2001 Jan-Feb; 7:17-20
HSL7831
Ellen EF.
Visits From Pharmaceutical Reps
Psychiatric Times 2001 Jan; 18:(1):
http://www.psychiatrictimes.com/p010121.html
HSL32
Woloshin S, Schwartz LM, Tremmel J, Welch HG
Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?
Lancet 2001; 358:1141-1146
http://linkinghub.elsevier.com/retrieve/pii/S0140673601062547
HSL34
Vlassov V, Mansfield P, Lexchin J, Vlassova A.
Do drug advertisements in Russian medical journals provide essential information for safe prescribing?
West J Med 2001; 174:391-394
HSL36
Robinson J.
Prescription games: money, ego, and power inside the global pharmaceutical industry
Toronto: McClelland and Stewart 2001
http://www.amazon.co.uk/exec/obidos/ASIN/0771075685/qid=1124431439/sr=1-3/ref=sr_1_10_3/026-3368758-1517268
HSL37
Montaner JSG, O'Shaughnessy MV, Schechter MT.
Industry-sponsored clinical research: a double-edged sword
Lancet 2001; 385:1893-1895
HSL38
Lill DJ, Peterson RT.
Older adult portrayal in television commercials by pharmaceutical manufacturers: an analysis
Journal of Pharmaceutical Marketing & Management 2001; 14:(1):81-96
HSL39
Lewis S, Baird P, Evans RG, Ghali WA, Wright CJ, Gibson E, et al
Dancing with the porcupine: rules for governing the university-industry relationship
Can Med Assoc J 2001; 165:783-785
http://www.cmaj.ca/cgi/content/full/165/6/783
HSL40
Kemmeren JM, Algra A, Grobbee DE.
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
BMJ 2001; 323:131-134
http://bmj.bmjjournals.com/cgi/content/full/323/7305/131
HSL42
Gönül FF, Carter F, Petrova E, Srinivasan K.
Promotion of prescription drugs and its impact on physicians' choice behavior
Journal of Marketing 2001; 65:79-90
HSL43
Findlay SD.
Direct-to-consumer promotion of prescription drugs: economic implications for patients, payers and providers
Pharmacoeconomics 2001; 19:(2):109-199
HSL1819
Okoro EO, Davies AE.
Sponsorship of educational programmes in Nigerian medical and pharmacy schools by pharmaceutical companies: possible risk implication for public health.
Ethics Med 2001 Spr; 17:(1):52-60
HSL2053
Ainslie G.
Breakdown of Will
Cambridge: Cambridge University Press 2001
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521596947
Page 139 of 144 pages ‹ First < 137 138 139 140 141 > Last ›
